[Effect of beta sympatholytic agent ICI 50172 (Dalzic) in various cardiovascular diseases].
D000083:Acetanilides / Q000627:therapeutic use; D000293:Adolescent; D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000605:Amino Alcohols / Q000627:therapeutic use*; D001146:Arrhythmia, Sinus / Q000188:drug therapy; D001786:Blood Glucose; D001794:Blood Pressure / Q000187:drug effects; D001980:Bronchi / Q000187:drug effects; D005117:Cardiac Complexes, Premature / Q000188:drug therapy; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D002784:Cholesterol / Q000097:blood; D003327:Coronary Disease / Q000188:drug therapy; D004064:Digestive System / Q000187:drug effects; D004562:Electrocardiography; D005080:Exercise Test; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D011437:Propylamines / Q000627:therapeutic use; D013610:Tachycardia / Q000188:drug therapy
D000083:Acetanilides; D000319:Adrenergic beta-Antagonists; D000605:Amino Alcohols; D001786:Blood Glucose; D008055:Lipids; D011437:Propylamines; D002784:Cholesterol
Uber die Wirkung des Beta-Sympathikolytikums ICI 50172 (Dalzic) bei verschiedenen kardiovaskulären Erkrankungen.